Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
PLoS Med ; 7(4): e1000264, 2010 Apr 20.
Article in English | MEDLINE | ID: mdl-20421922

ABSTRACT

BACKGROUND: Approximately one-quarter of all pregnancy- and delivery-related maternal deaths worldwide occur in India. Taking into account the costs, feasibility, and operational complexity of alternative interventions, we estimate the clinical and population-level benefits associated with strategies to improve the safety of pregnancy and childbirth in India. METHODS AND FINDINGS: Country- and region-specific data were synthesized using a computer-based model that simulates the natural history of pregnancy (both planned and unintended) and pregnancy- and childbirth-associated complications in individual women; and considers delivery location, attendant, and facility level. Model outcomes included clinical events, population measures, costs, and cost-effectiveness ratios. Separate models were adapted to urban and rural India using survey-based data (e.g., unmet need for birth spacing/limiting, facility births, skilled birth attendants). Model validation compared projected maternal indicators with empiric data. Strategies consisted of improving coverage of effective interventions that could be provided individually or packaged as integrated services, could reduce the incidence of a complication or its case fatality rate, and could include improved logistics such as reliable transport to an appropriate referral facility as well as recognition of referral need and quality of care. Increasing family planning was the most effective individual intervention to reduce pregnancy-related mortality. If over the next 5 y the unmet need for spacing and limiting births was met, more than 150,000 maternal deaths would be prevented; more than US$1 billion saved; and at least one of every two abortion-related deaths averted. Still, reductions in maternal mortality reached a threshold ( approximately 23%-35%) without including strategies that ensured reliable access to intrapartum and emergency obstetrical care (EmOC). An integrated and stepwise approach was identified that would ultimately prevent four of five maternal deaths; this approach coupled stepwise improvements in family planning and safe abortion with consecutively implemented strategies that incrementally increased skilled attendants, improved antenatal/postpartum care, shifted births away from home, and improved recognition of referral need, transport, and availability/quality of EmOC. The strategies in this approach ranged from being cost-saving to having incremental cost-effectiveness ratios less than US$500 per year of life saved (YLS), well below India's per capita gross domestic product (GDP), a common benchmark for cost-effectiveness. CONCLUSIONS: Early intensive efforts to improve family planning and control of fertility choices and to provide safe abortion, accompanied by a paced systematic and stepwise effort to scale up capacity for integrated maternal health services over several years, is as cost-effective as childhood immunization or treatment of malaria, tuberculosis, or HIV. In just 5 y, more than 150,000 maternal deaths would be averted through increasing contraception rates to meet women's needs for spacing and limiting births; nearly US$1.5 billion would be saved by coupling safe abortion to aggressive family planning efforts; and with stepwise investments to improve access to pregnancy-related health services and to high-quality facility-based intrapartum care, more than 75% of maternal deaths could be prevented. If accomplished over the next decade, the lives of more than one million women would be saved.


Subject(s)
Cost-Benefit Analysis/methods , Maternal Mortality , Family Planning Services , Female , Humans , India , Maternal Health Services , Pregnancy
2.
Afr J Reprod Health ; 14(2): 85-103, 2010 Jun.
Article in English | MEDLINE | ID: mdl-21243922

ABSTRACT

To explore the policy implications of increasing access to safe abortion in Nigeria and Ghana, we developed a computer-based decision analytic model which simulates induced abortion and its potential complications in a cohort of women, and comparatively assessed the cost-effectiveness of unsafe abortion and three first-trimester abortion modalities: hospital-based dilatation and curettage, hospital- and clinic-based manual vacuum aspiration (MVA), and medical abortion using misoprostol (MA). Assuming all modalities are equally available, clinic-based MVA is the most cost-effective option in Nigeria. If clinic-based MVA is not available, MA is the next best strategy. Conversely, in Ghana, MA is the most cost-effective strategy, followed by clinic-based MVA if MA is not available. From a real world policy perspective, increasing access to safe abortion in favor over unsafe abortion is the single most important factor in saving lives and societal costs, and is more influential than the actual choice of safe abortion modality.


Subject(s)
Abortion, Induced/economics , Cost-Benefit Analysis , Abortifacient Agents, Nonsteroidal/economics , Decision Support Techniques , Dilatation and Curettage/economics , Female , Ghana , Humans , Markov Chains , Misoprostol/economics , Nigeria , Pregnancy , Pregnancy Trimester, First , Vacuum Curettage/economics
3.
African Journal of Reproductive Health ; 14(2): 85-103, 2010. ilus
Article in English | AIM (Africa) | ID: biblio-1258459

ABSTRACT

To explore the policy implications of increasing access to safe abortion in Nigeria and Ghana, we developed a computer-based decision analytic model which simulates induced abortion and its potential complications in a cohort of women, and comparatively assessed the cost-effectiveness of unsafe abortion and three first-trimester abortion modalities: hospital-based dilatation and curettage, hospital- and clinic-based manual vacuum aspiration (MVA), and medical abortion using misoprostol (MA). Assuming all modalities are equally available, clinic-based MVA is the most cost-effective option in Nigeria. If clinic-based MVA is not available, MA is the next best strategy. Conversely, in Ghana, MA is the most cost-effective strategy, followed by clinic-based MVA if MA is not available. From a real world policy perspective, increasing access to safe abortion in favor over unsafe abortion is the single most important factor in saving lives and societal costs, and is more influential than the actual choice of safe abortion modality (Afr. J. Reprod. Health 2010; 14[2]: 85-103)


Subject(s)
Abortion, Induced , Abortion, Legal , Cost-Benefit Analysis , Ghana , Nigeria , Pregnancy Trimester, First , Pregnancy Trimester, Second
4.
Am J Obstet Gynecol ; 198(5): 500.e1-7, 2008 May.
Article in English | MEDLINE | ID: mdl-18455524

ABSTRACT

OBJECTIVE: The purpose of this study was (1) to estimate the direct medical costs of 7 major noncervical human papillomavirus (HPV)-related conditions that include genital cancers, mouth and oropharyngeal cancers, anogenital warts, and juvenile-onset recurrent respiratory papillomatosis, and (2) to approximate the economic burden of noncervical HPV disease. STUDY DESIGN: For each condition, we synthesized the best available secondary data to produce lifetime cost per case estimates, which were expressed in present value. Using an incidence-based approach, we then applied these costs to develop an aggregate measure of economic burden. RESULTS: The economic burden that was associated with noncervical HPV-6-, -11-, -16-, and -18-related conditions in the US population in the year 2003 approximates $418 million (range, $160 million to $1.6 billion). CONCLUSION: The economic burden of noncervical HPV disease is substantial. Analyses that assess the value of investments in HPV prevention and control programs should take into account the costs and morbidity and mortality rates that are associated with these conditions.


Subject(s)
Cost of Illness , Neoplasms/economics , Neoplasms/virology , Papillomavirus Infections/economics , Anus Neoplasms/economics , Anus Neoplasms/epidemiology , Anus Neoplasms/virology , Costs and Cost Analysis , Female , Human papillomavirus 11 , Human papillomavirus 16 , Human papillomavirus 18 , Human papillomavirus 6 , Humans , Male , Mouth Neoplasms/economics , Mouth Neoplasms/virology , Neoplasms/epidemiology , Oropharyngeal Neoplasms/economics , Oropharyngeal Neoplasms/epidemiology , Oropharyngeal Neoplasms/virology , Papilloma/economics , Papilloma/virology , Papillomavirus Infections/prevention & control , Penile Neoplasms/economics , Penile Neoplasms/epidemiology , Penile Neoplasms/virology , Pharyngeal Neoplasms/economics , Pharyngeal Neoplasms/virology , Respiratory Tract Neoplasms/economics , Respiratory Tract Neoplasms/virology , United States/epidemiology , Vaginal Neoplasms/economics , Vaginal Neoplasms/epidemiology , Vaginal Neoplasms/virology , Vulvar Neoplasms/economics , Vulvar Neoplasms/epidemiology , Vulvar Neoplasms/virology , Warts/economics
5.
PLoS One ; 2(8): e750, 2007 Aug 15.
Article in English | MEDLINE | ID: mdl-17710149

ABSTRACT

BACKGROUND: In Mexico, the lifetime risk of dying from maternal causes is 1 in 370 compared to 1 in 2,500 in the U.S. Although national efforts have been made to improve maternal services in the last decade, it is unclear if Millennium Development Goal 5--to reduce maternal mortality by three-quarters by 2015--will be met. METHODOLOGY/PRINCIPAL FINDINGS: We developed an empirically calibrated model that simulates the natural history of pregnancy and pregnancy-related complications in a cohort of 15-year-old women followed over their lifetime. After synthesizing national and sub-national trends in maternal mortality, the model was calibrated to current intervention-specific coverage levels and validated by comparing model-projected life expectancy, total fertility rate, crude birth rate and maternal mortality ratio with Mexico-specific data. Using both published and primary data, we assessed the comparative health and economic outcomes of alternative strategies to reduce maternal morbidity and mortality. A dual approach that increased coverage of family planning by 15%, and assured access to safe abortion for all women desiring elective termination of pregnancy, reduced mortality by 43% and was cost saving compared to current practice. The most effective strategy added a third component, enhanced access to comprehensive emergency obstetric care for at least 90% of women requiring referral. At a national level, this strategy reduced mortality by 75%, cost less than current practice, and had an incremental cost-effectiveness ratio of $300 per DALY relative to the next best strategy. Analyses conducted at the state level yielded similar results. CONCLUSIONS/SIGNIFICANCE: Increasing the provision of family planning and assuring access to safe abortion are feasible, complementary and cost-effective strategies that would provide the greatest benefit within a short-time frame. Incremental improvements in access to high-quality intrapartum and emergency obstetric care will further reduce maternal deaths and disability.


Subject(s)
Maternal Health Services/economics , Maternal Mortality/trends , Models, Economic , Pregnancy Complications/economics , Pregnancy Outcome/economics , Adolescent , Cost-Benefit Analysis , Delivery, Obstetric/economics , Emergency Service, Hospital/economics , Family Planning Services/economics , Female , Health Care Costs/statistics & numerical data , Humans , Longitudinal Studies , Mexico , Pregnancy , Pregnancy Complications/therapy , Treatment Outcome
6.
Sex Transm Dis ; 33(7): 428-36, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16572038

ABSTRACT

OBJECTIVE/GOAL: To understand the potential impact of assumptions about the natural history of untreated Chlamydia trachomatis on the cost-effectiveness of screening strategies. STUDY DESIGN: Using a previously developed state-transition model, we explored how alternative assumptions about the natural history of disease following infection affect the estimated cost-effectiveness of screening for U.S. women. The analysis was conducted from a modified societal perspective and incorporated a lifetime analytic horizon. RESULTS: Different natural history assumptions affect cost-effectiveness outcomes. Assumptions about the combined risk of persistent and repeat infections have the greatest impact on the composition of optimal screening strategies, whereas assumptions about the risk of pelvic inflammatory disease most greatly influenced the magnitude of incremental cost-effectiveness ratios. CONCLUSIONS: Priorities for future C trachomatis research should include better estimates of the risk of pelvic inflammatory disease, persistence, and repeat infection. Better delineation of these variables will permit improved evaluation of potential screening activities.


Subject(s)
Chlamydia Infections/diagnosis , Chlamydia trachomatis , Mass Screening/economics , Quality-Adjusted Life Years , Adolescent , Adult , Chlamydia Infections/complications , Chlamydia Infections/economics , Cost-Benefit Analysis , Female , Humans , Markov Chains , Mass Screening/methods , Models, Theoretical , Pelvic Inflammatory Disease/etiology , Risk Factors , United States/epidemiology
7.
Ann Intern Med ; 141(7): 501-13, 2004 Oct 05.
Article in English | MEDLINE | ID: mdl-15466767

ABSTRACT

BACKGROUND: Clinical guidelines have traditionally advised annual Chlamydia trachomatis screening for women younger than 25 years of age. OBJECTIVE: To assess the cost-effectiveness of recently proposed strategies for chlamydia screening. DESIGN: State transition simulation model; cost-effectiveness analysis. DATA SOURCES: Published literature. TARGET POPULATION: Sexually active U.S. women 15 to 29 years of age. TIME HORIZON: Lifetime. PERSPECTIVE: Modified societal. INTERVENTIONS: Four strategies targeted to 3 specific age groups (15 to 19 years, 15 to 24 years, and 15 to 29 years): 1) no screening, 2) annual screening for all women, 3) annual screening followed by 1 repeated test within 3 to 6 months after a positive test result, and 4) annual screening followed by selective semiannual screening for women with a history of infection. OUTCOME MEASURES: Clinical events (for example, pelvic inflammatory disease, chronic pelvic pain, ectopic pregnancy, and infertility), lifetime costs, quality-adjusted life expectancy, and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Annual screening in women 15 to 29 years of age followed by semiannual screening for those with a history of infection was the most effective and cost-effective strategy. It consistently had an incremental cost-effectiveness ratio less than 25,000 dollars per quality-adjusted life-year (QALY) compared with the next most effective strategy. When the indirect transmission effects of a 10-year screening program on the probability of infection in uninfected women (that is, per-susceptible rate of infection) were considered, all strategies became more cost-effective. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to the annual incidence of chlamydia, probability of persistent infection, screening test costs, and costs of treating long-term complications. Each variable was associated with threshold values beyond which screening became cost-saving. In probabilistic analysis, annual screening in women 15 to 29 years of age followed by semiannual screening for those with a history of infection had an incremental cost-effectiveness ratio less than 50,000 dollars per QALY in 99% of simulations. LIMITATIONS: Uncertainty about the natural history of chlamydial infection and consideration of only the indirect transmission effects of C. trachomatis screening. CONCLUSIONS: Annual C. trachomatis screening for all women 15 to 29 years of age and selective targeting of those with a history of infection for semiannual screening is very cost-effective compared with other well-accepted clinical interventions.


Subject(s)
Chlamydia Infections/diagnosis , Chlamydia trachomatis , Mass Screening/economics , Adolescent , Adult , Chlamydia Infections/drug therapy , Chlamydia Infections/prevention & control , Computer Simulation , Cost-Benefit Analysis , Female , Health Care Costs , Humans , Quality-Adjusted Life Years , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...